Proton MRS of the unilateral substantia nigra in the human brain at 4 tesla: Detection of high GABA concentrations

Parkinson's disease (PD) is characterized by loss of dopaminergic neurons in the substantia nigra (SN), the cause of which is unknown. Characterization of early SN pathology could prove beneficial in the treatment and diagnosis of PD. The present study shows that with the use of short‐echo (5 ms) Stimulated‐Echo Acquisition Mode (STEAM) spectroscopy and LCModel, a neurochemical profile consisting of 10 metabolites, including γ‐aminobutyric acid (GABA), glutamate (Glu), and glutathione (GSH), can be measured from the unilateral SN at 4 tesla. The neurochemical profile of the SN is unique and characterized by a fourfold higher GABA/Glu ratio compared to the cortex, in excellent agreement with established neurochemistry. The presence of elevated GABA levels in SN was validated with the use of editing, suggesting that partial volume effects were greatly reduced. These findings establish the feasibility of obtaining a neurochemical profile of the unilateral human SN by single‐voxel spectroscopy in small volumes. Magn Reson Med, 2006. © 2006 Wiley‐Liss, Inc.

[1]  T. Perry,et al.  GABA CONTENT AND GLUTAMIC ACID DECARBOXYLASE ACTIVITY IN BRAIN OF HUNTINGTON'S CHOREA PATIENTS AND CONTROL SUBJECTS 1 , 1975, Journal of neurochemistry.

[2]  T. Perry.  Cerebral Amino Acid Pools , 1982 .

[3]  C. W. Adams,et al.  Handbook of Neurochemistry , 1983, Springer US.

[4]  J. Degroot,et al.  Magnetic resonance imaging of the midbrain in Parkinson's disease , 1986, Annals of neurology.

[5]  R I Grossman,et al.  Magnetic resonance imaging in Parkinson's disease and parkinsonian syndromes , 1989, Neurology.

[6]  A Capdevila,et al.  Reduction of the substantia nigra width and motor decline in aging and Parkinson's disease. , 1992, Archives of neurology.

[7]  S. Provencher.  Estimation of metabolite concentrations from localized in vivo proton NMR spectra , 1993, Magnetic resonance in medicine.

[8]  P. Boesiger,et al.  T2 relaxation time in patients with Parkinson's disease , 1993, Neurology.

[9]  B D Ross,et al.  Absolute Quantitation of Water and Metabolites in the Human Brain. II. Metabolite Concentrations , 1993 .

[10]  Jullie W Pan,et al.  High frequency volume coils for clinical NMR imaging and spectroscopy , 1994, Magnetic resonance in medicine.

[11]  P. Hrdina.  Basic Neurochemistry: Molecular, Cellular and Medical Aspects. , 1996 .

[12]  H. K. Lee,et al.  Neuronal laterality in Parkinson's disease with unilateral symptom by in vivo 1H magnetic resonance spectroscopy. , 1998, Investigative radiology.

[13]  T. Hosoya,et al.  Evaluation of the substantia nigra in patients with Parkinsonian syndrome accomplished using multishot diffusion-weighted MR imaging. , 1999, AJNR. American journal of neuroradiology.

[14]  V. Govindaraju,et al.  Proton NMR chemical shifts and coupling constants for brain metabolites , 2000, NMR in biomedicine.

[15]  D. J. Brooks,et al.  Morphological and functional imaging studies on the diagnosis and progression of Parkinson’s disease , 2000, Journal of Neurology.

[16]  M Hutchinson,et al.  Structural changes of the substantia nigra in Parkinson's disease as revealed by MR imaging. , 2000, AJNR. American journal of neuroradiology.

[17]  R Gruetter,et al.  Field mapping without reference scan using asymmetric echo‐planar techniques , 2000, Magnetic resonance in medicine.

[18]  David J. Brooks,et al.  A comparison of 18F-dopa PET and inversion recovery MRI in the diagnosis of Parkinson’s disease , 2001, Neurology.

[19]  C. Clarke,et al.  Systematic review of proton magnetic resonance spectroscopy of the striatum in parkinsonian syndromes , 2001, European journal of neurology.

[20]  A. Schapira,et al.  Causes of neuronal death in Parkinson's disease. , 2001, Advances in neurology.

[21]  J V Hajnal,et al.  A comparison of (18)F-dopa PET and inversion recovery MRI in the diagnosis of Parkinson's disease. , 2001, Neurology.

[22]  Yoshiharu Tamakawa,et al.  The substantia nigra in Parkinson disease: proton density-weighted spin-echo and fast short inversion time inversion-recovery MR findings. , 2002, AJNR. American journal of neuroradiology.

[23]  J. O'Brien,et al.  A Comprehensive Review of Proton Magnetic Resonance Spectroscopy Studies in Dementia and Parkinson’s Disease , 2002, Dementia and Geriatric Cognitive Disorders.

[24]  N. Schuff,et al.  Quantitative 1H magnetic resonance spectroscopy and MRI of Parkinson's disease , 2002, Movement disorders : official journal of the Movement Disorder Society.

[25]  Rolf Gruetter,et al.  Direct in vivo measurement of human cerebral GABA concentration using MEGA‐editing at 7 Tesla , 2002, Magnetic resonance in medicine.

[26]  M. Horne,et al.  Comparison of the basal ganglia in rats, marmosets, macaques, baboons, and humans: Volume and neuronal number for the output, internal relay, and striatal modulating nuclei , 2002, The Journal of comparative neurology.

[27]  K. Lee,et al.  Proton MR spectroscopic changes in Parkinson's diseases after thalamotomy. , 2003, European journal of radiology.

[28]  Rolf Gruetter,et al.  Measurement of reduced glutathione (GSH) in human brain using LCModel analysis of difference‐edited spectra , 2003, Magnetic resonance in medicine.

[29]  C. Clarke.  Neuroprotection and pharmacotherapy for motor symptoms in Parkinson's disease , 2004, The Lancet Neurology.

[30]  C. Wasterlain,et al.  GABA metabolism in the substantia nigra, cortex, and hippocampus during status epilepticus , 1993, Neurochemical Research.

[31]  R. Gruetter,et al.  Methodology of1H NMR spectroscopy of the human brain at very high magnetic fields , 2005, Applied magnetic resonance.

[32]  R. Gruetter,et al.  Assessment of adrenoleukodystrophy lesions by high field MRS in non-sedated pediatric patients , 2005, Neurology.